Inactive Instrument

Merck & Co., Inc. Stock Euronext Paris

Equities

MRK

US58933Y1055

Pharmaceuticals

Sales 2024 * 64.18B 59.78B Sales 2025 * 68.68B 63.98B Capitalization 331B 308B
Net income 2024 * 19.51B 18.17B Net income 2025 * 22.25B 20.72B EV / Sales 2024 * 5.45 x
Net Debt 2024 * 18.6B 17.33B Net Debt 2025 * 7.28B 6.78B EV / Sales 2025 * 4.93 x
P/E ratio 2024 *
16.9 x
P/E ratio 2025 *
14.6 x
Employees 71,000
Yield 2024 *
2.37%
Yield 2025 *
2.5%
Free-Float 70.77%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 57 14-03-31
Director of Finance/CFO 55 89-12-31
Chief Tech/Sci/R&D Officer 55 20-07-31
Members of the board TitleAgeSince
Director/Board Member 63 07-11-26
Director/Board Member 67 15-08-31
Director/Board Member 69 18-02-28
More insiders
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company